What Happened?
Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.3% in the afternoon session after its first-quarter results, although beating expectations, were overshadowed by concerns about its future growth prospects.
The company reported a 2.6% year-over-year revenue decline to $150.8 million and a narrowed loss per share, both of which surpassed Wall Street’s forecasts. However, the positive surprise was not enough to lift investor sentiment. While 10x Genomics reconfirmed its full-year revenue guidance, the market appeared to focus on the underlying sales dip and analyst expectations of a further revenue decline over the next year. This suggests that investors are cautious about the company’s ability to accelerate its growth in the near term.
The shares closed the day at $21.61, down 3.6% from previous close.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy 10x Genomics? Access our full analysis report here, it’s free.
What Is The Market Telling Us
10x Genomics’s shares are extremely volatile and have had 54 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 15 days ago when the stock dropped 5.4% on the news that a key industry peer, Thermo Fisher Scientific (TMO), reported mixed first-quarter results, sparking concerns about a potential slowdown in the life sciences sector.
Thermo Fisher, a major player in the scientific instruments and lab supplies market, announced quarterly revenue of $11.01 billion, which was higher than analyst expectations. However, the company’s organic revenue growth, which measures sales increases from its existing business operations, excluding acquisitions, came in at 1%, below the 1.4% analysts had forecasted. This weaker-than-expected core growth from a market leader like Thermo Fisher can signal slowing demand across the industry.
Consequently, investors may be concerned that 10x Genomics could face similar headwinds, leading to a sell-off in its shares.
10x Genomics is up 29.9% since the beginning of the year, but at $21.59 per share, it is still trading 17.2% below its 52-week high of $26.08 from April 2026. Despite the year-to-date gain, investors who bought $1,000 worth of 10x Genomics’s shares 5 years ago would now be looking at only $160.12.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
